1Jones PA, Baylin SB. The epigenomies of cancer [J]. Cell, 2007,128:683.
2Silverman LR, Holland JF, Weinberg RS,et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastie syndromes [J]. Leukemia, 1993,7 (Suppl. 1) : 21.
3Silverman LR, McKenzie DR, Peterson BL, et al. Response rates in patients with acute myeloid leukemia, treated with azacytidine, using WHO and intenrational working group criteria for myelodysplastic syndrome [J]. Blood, 2005,106 : 525a.
4Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B [J]. J Clin Oncol, 2002,20 : 2429.
5Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421,8921, and 9221 by the Cancer and Leukemia Group B [J]. J Clin Oncol, 2006, 24:2895.
6Fenaux P, Mufti G, Santini V, et al. Azacitidine treatment prolongs overall survival in higher risk MDS paticats compared with conventional care regimens: results of the AZA-001 phase III study [J]. Blood, 2007,110:250a.
7Kaminskas E, Farrell A, Abraham S,et al. Approval summary: azaeitidine for treatment of myelodysplastiC syndrome subtypes [J]. Clin Cancer Res, 2005,11 :3604.
9Lyons R, Cosgriff T, Modi S, et al. Azacytidine(Vidaza) treatment response assessed using three alternative dosing schedules in patients with myelodysplastic syndromes [J]. Blood, 2005,106 : 707a.
10Rossetti J, Falke E, Shadduck R, et al. G-CSF increases hematological responses among patients with myelodysplasia treated with azacitidine [J]. Blood, 2006, 108: 303b.
2Marx PF,Verkleij CJ,Valls Seron M,et al.Recent developments in thrombin-activatable fibrinolysis inhibitor research[J].Mini Rey Med Chem,2009,9(10):1165-1173.
3Vasse M.Protein Z,a protein seeking a pathology[J].Thromb Haemost,2008,100(4):548-556.
5Holliday R. Epigenetics:a historical overview[J].Epigenetics,2006,(02):76-80.
6Fathi AT,Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy[J/OL].Adv Hematol,2012.469592.
7Garcia-Manero G. Modifying the epigenome as a therapeutic strategy in myelodysplasia[J/OL].Hematology：Am Soc Hematol Educ Program Book,2007,(1):405-411.
8Blum W. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes[J/OL].Hematology：Am Soc Hematol Educ Program Book,2010,(1):314-321.
9Issa JP,Kantarjian HM. Targeting DNA methylation[J].{H}Clinical Cancer Research,2009,(12):3938-3946.
10Sekeres MA. Treatment of MDS：something old, something new, something borrowed.[J/OL].Hematology：Am Soc Hematol Educ Program Book,2009,(1):656-663.
